BridgeBio Pharma (BBIO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$713.1M

Revenue (quarter)

$243.7M

Revenue growth (year over year)

+120.39%

Gross profit (trailing twelve months)

$673.4M

Gross margin

94.44%

Net income (trailing twelve months)

−$702.0M

Net income (quarter)

−$155.9M

Net income growth (year over year)

+15.17%

Net margin

−98.45%

Return on equity

—

EPS (trailing twelve months)

−$3.56

Book value per share

−$12.88

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

305.86%

Payout ratio

—

Dividend yield

—

Company profile

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

• Is BridgeBio Pharma (BBIO) profitable?

  No. BridgeBio Pharma reported a net loss of $702.0M over the trailing twelve months.

• How much revenue does BridgeBio Pharma (BBIO) make?

  BridgeBio Pharma generated $713.1M in revenue over the trailing twelve months, up 120.39% year over year.

• How do I buy stock in BridgeBio Pharma (BBIO)?

  BBIO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.